Ovid Therapeutics announced promising advancements in their epilepsy pipeline with OV329 showing safety and tolerability, leading to upcoming Phase 2 trials. Additionally, funding from a $60 million private placement supports expansions into tuberous sclerosis complex and infantile spasms. Ovid's cash position ensures operational stability through late 2028, which may positively influence investor confidence.
- Ovid Therapeutics reported a quarterly loss of $0.17 per share, beating estimates by 26.09%. - Revenue for Ovid increased to $0.15 million, exceeding the Zacks Consensus Estimate by 40.95%. - Ovid's stock has lost 6.2% year-to-date, underperforming the S&P 500. - Management's commentary on earnings call will impact stock's immediate movement. - Estimate revisions for Ovid Therapeutics are currently mixed. Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Earnings
